INTRODUCTION {#s1}
============

Epigenetics refers to heritable changes in gene expression not related to changes in the DNA sequence \[[@R1]\]; they occur primarily through DNA methylation and histone post-translational modifications. Epigenetic changes have been associated with specific patterns of gene expression and are early events in different cancer types, including head and neck squamous cell carcinoma (HNSCC) \[[@R2]\]. In mammals, DNA methylation occurs predominantly at CpG dinucleotides. DNA methyl transferase (DNMT) transfers a methyl group to cytosine, generating 5-methylcytosine \[[@R3]\]. Low methylation levels within the promoter region have been associated with either gene activation or chromosome instability \[[@R4]\].

Lack or reduction of DNMT activity implies gradual and passive loss of DNA methylation, so that DNMTs inhibition is an important mechanism of the passive DNA demethylation process. DNA demethylation also occurs through an active mechanism, independent of cell division, which is mediated by enzymes of the TET family. These enzymes firstly modify methylated cytosine, which is subsequently replaced by the DNA repair machinery \[[@R5], [@R6]\].

Changes in chromatin dynamics is an early abnormality described in cancer \[[@R7]\]. The basic unit of chromatin is the nucleosome, which is formed by DNA and histone proteins \[[@R8]\]. Histones undergo many modifications in their N-terminal tails, among which lysine acetylation is the most studied one. Histone deacetylases (HDAC) remove the acetyl radical present in the lysine residues of histones, whereas histone acetyltransferases (HAT) add acetyl radicals to those positions \[[@R1]\]. The chromatin organization results from post-translational modifications of histone tails, DNA methylation patterns, and nucleosome positioning. In cancer cells, chromatin remodeling, methylation signatures, and consequently, gene expression profiles, become disturbed \[[@R7]\].

SET oncoprotein (I2PP2A or TAF-1β), which is accumulated in HNSCC \[[@R9]\], is involved in many aspects related to chromatin structure. SET protein is characterized as (*i*) an histone chaperone required for chromatin transcription \[[@R10], [@R11]\], (*ii*) an important regulator of chromosome condensation \[[@R12]\], (*iii*) a member of the Inhibitor of Histone Acetyltransferase (INHAT) complex that inhibits histone acetylation by binding to and masking histone acetyltransferases targets \[[@R13]\], and (*iv*) an inhibitor of active DNA demethylation \[[@R14]\]. In this context, it is unknown whether SET accumulation in cells either modifies specific targets or is associated with transcriptional repression or activation. Here, we addressed this issue. Overall, we demonstrated that SET promotes a global DNA demethylation in HNSCC cells, through active signaling, increasing TET1 and 5-hydroxymethylcytosine levels. Demethylation is not always followed by reactivation of gene expression.

RESULTS {#s2}
=======

SET accumulation is associated with global loss of DNA methylation in HNSCC {#s2_1}
---------------------------------------------------------------------------

To investigate how SET protein accumulation influences the epigenetic control of gene expression, we analysed the DNA methylation profile in two non-tumour cell lines, HEK293 and NOK-SI, with and without SET overexpression (HEK293/SET and NOK-SI/SET, respectively), and three HNSCC cell lines, HN6, HN12, and HN13, which present SET constitutively accumulated \[[@R15]\], with and without SET knockdown (HN6siSET, HN12siSET, and HN13siSET, respectively). As the oncogene SET is a potent inhibitor of the tumour suppressor PP2A \[[@R16], [@R17]\], and inhibits other tumour suppressors such as PTEN \[[@R18]\] and TP53 \[[@R19]\], we examined how SET accumulation affects DNA methylation using a panel of known tumour suppressor genes by means of EpiTect Methyl qPCR arrays (Figure [1A](#F1){ref-type="fig"}). Notably, SET protein accumulation, a common event in HNSCC \[[@R15]\], promoted loss of DNA methylation (Figure [1A](#F1){ref-type="fig"} - black arrows). Next, we analysed the average methylation change to know how much the changes in SET levels would influence the methylation profile. We calculated the ratio of CpGs methylated between control and up- or downregulated SET samples (Figure [1B](#F1){ref-type="fig"}). SET-accumulating cells displayed decreased average DNA methylation (Figure [1B](#F1){ref-type="fig"} - red arrows), while the HNSCC cell lines with knocked down SET displayed increased average DNA methylation (Figure [1B](#F1){ref-type="fig"} -- green arrows); these findings suggest that SET accumulation influences DNA methylation.

![SET protein promotes loss of DNA methylation\
(**A**) Normal cell lines HEK293 and NOK-SI -- control and overexpressing SET protein (HEK293/SET and NOK-SI/SET) --, and HNSCC cell lines HN6, HN12, and HN13 -- control and with SET knockdown (HN6siSET, HN12siSET, and HN13siSET, respectively) -- were used to assess the methylation profile of tumor suppressor genes. An empty vector and the siControl AllStar siRNA negative control oligonucleotide were used as controls for SET overexpression and SET knockdown, respectively. DNA was extracted with phenol:chloroform and the DNA methylation profile was assessed using EpiTect Methyl PCR array (Qiagen), according to the manufacturer\'s instructions. After qPCR assay, data were analyzed using PCR array Data Analysis Software (Qiagen). The heat map indicates hypomethylated genes in green and hypermethylated genes in red. (**B**) Graphic representation of the methylation average changes in cells after SET knockdown or overexpression. We calculated the ratio of changes in CpG methylation levels between control and SET up- or downregulated samples. (**C**) Flow cytometry assay was used to quantify global methylation levels though 5-methylcytidine accumulation in HEK293, HEK293/SET, HN12, and HN12siSET cells. Cells without antibody staining were used as negative control (no staining). Assays were performed in triplicate. \*(*p* \< 0.05), \*\*(*p* \< 0.01), and \*\*\*(*p* \< 0.001).](oncotarget-08-26802-g001){#F1}

To confirm these results, we analysed the cellular levels of 5-methylcytidine, which is commonly used to assess the full genome methylation profile \[[@R20]\]. We selected the HN12 cell line -- which exhibited the most marked change in average DNA methylation after SET knockdown (Figure [1B](#F1){ref-type="fig"}) -- and the non-tumour cell line HEK293 (Figure [1C](#F1){ref-type="fig"}) for the assay. Compared with HEK293 cells, HEK293/SET cells significantly lost 5-methylcytidine, while HN12 cells exhibited low 5-methylcytidine levels. As expected, HN12siSET cells had increased 5-methylcytidine levels. These results indicate that SET modulates DNA methylation levels in HNSCC.

Given that DNA methylation is an epigenetic mechanism for silencing gene expression, we performed qPCR to assess the expression levels of four genes that were hypomethylated by SET accumulation: *BRCA1*, *GSTP1*, *MLH1*, and *PTEN* (Figure [2A](#F2){ref-type="fig"}). They were analysed in HEK293, HN12, and HN13 cells. SET overexpression in HEK293 cells upregulated *BRCA1* and *MLH1* expression, but downregulated *GSTP1* and *PTEN* expression (Figure [2A](#F2){ref-type="fig"} -- HEK293 column). Compared with the basal expression levels in the non-tumour cell line HEK293, used as calibrator, the expression levels of all four genes were lowered in HN12 and HN13 tumour cells (Figure [2A](#F2){ref-type="fig"} -- red bars) but increased after SET knockdown (Figure [2A](#F2){ref-type="fig"} -- green bars). Thus, high SET levels in tumour cells directly correlated with diminished expression of these genes. This finding was unexpected because SET accumulation is associated with loss of DNA methylation, which activates the expression of genes that are typically silenced by methylation \[[@R21]\]. A plausible explanation is that DNA methylation responds differently to the gene expression control machinery due to the interaction with other factors, including histone modifiers \[[@R22]\]. In addition, SET negatively regulates the expression of genes involved in cellular detoxification \[[@R23]\] and also participates as a subunit of the inhibitor of histone acetyltransferases complex that represses transcription \[[@R24]\], suggesting that the SET controls gene expression through a DNA methylation-independent mechanism. Considering that SET, as a member of the INHAT complex, can directly bind to histones at promoters, to prevent acetylation \[[@R13], [@R24]\], we assessed the SET-promoter interaction using the chromatin immunoprecipitation assay (ChIP) for two genes whose expressions were decreased by SET accumulation: *GSTP1* and *PTEN* (Figure [2A](#F2){ref-type="fig"}). Both genes demonstrated association with SET at the promoter in all SET-accumulating cells, but not in HEK293 cells, which do not accumulate SET (Figure [2B](#F2){ref-type="fig"}).

![Loss of DNA methylation driven by SET protein does not necessarily activate gene expression\
(**A**) Quantitative PCR was performed in HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells to evaluate whether tumor suppressor genes expression was affected by DNA methylation. *BRCA1*, *MLH1*, and *PTEN* were assessed through TaqMan probes and *GSTP1* through SybrGreen primers. Graphics represent relative quantification of experiments performed in triplicate through 2^−ΔΔCt^ method. CDNA from HEK293 was used as calibrator and GAPDH and β-globin primers were used as housekeeping. (**B**) Chromatin immunoprecipitation assay was performed to identify whether SET interacts with *GSTP1* and *PTEN* promoters. Conventional PCR using DNA immunoprecipitated with antibody against SET was performed in triplicate. Ctrl lanes represent samples immunoprecipitated with anti-IgG antibody; INPUT samples consist of total DNA, and SET lanes refer to DNA immunoprecipitated with anti-SET antibody.](oncotarget-08-26802-g002){#F2}

Active DNA demethylation is the mechanism activated by SET for the loss of methylation {#s2_2}
--------------------------------------------------------------------------------------

DNMTs are responsible for the establishment and maintenance of DNA methylation. In this regard, DNMT inhibition is the main mechanism of passive DNA demethylation \[[@R5]\]. Given that DNA methylation pattern is maintained through cell division by DNMT1 activation \[[@R25]\], we assessed whether SET overexpression reduces DNMT1 levels in HEK293, HN12, and HN13 cells, using an immunofluorescence assay. Remarkably, all SET-accumulating cells exhibited increased DNMT1 levels, and SET knockdown decreased DNMT1 levels (Figure [3A](#F3){ref-type="fig"}). As SET accumulation is associated with reduced DNA methylation, we would expect that SET overexpression downregulated DNMT1; then, we also assessed DNMT activity using the same cell lines. Accordingly, SET accumulation and downregulation were associated with augmented and diminished DNMT activity, respectively (Figure [3B](#F3){ref-type="fig"}).

![DNA methyltransferases are not involved in DNA demethylation process mediated by SET accumulation\
. (**A**) Immunofluorescence assay was performed in HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells to determine the levels of DNMT1, the enzyme responsible for DNA methylation maintenance. Cells from five fields were measured using ImageJ software. Graphics represent the percentage of DNMT1-positive cells. Red arrows indicate SET accumulation; green arrows indicate SET downregulation. (**B**) DNA methyltransferases enzymatic activity assay using nuclear protein extract from cells; this assay was perfomed using EpiSeeker DNMT Activity Quantification Kit (Abcam), according to the manufacturer\'s protocol. Graphic represents experiments performed in triplicate. \*(*p* \< 0.05),\*\*(*p* \< 0.01) and \*\*\*(*p* \< 0.001).](oncotarget-08-26802-g003){#F3}

DNA demethylation can also occur through an active mechanism. Active DNA demethylation is an enzymatic process that removes the methyl group from 5-methylcytosine by breaking carbon-carbon bonds \[[@R26]\]. One of the active DNA demethylation mechanisms involves the oxidation of 5-methylcytosine, which is converted into 5-hydroxymethylcytosine by TET enzymes \[[@R6]\]. Here, we used an immunofluorescence assay to determine the TET1 protein levels in HEK293, HN12, and HN13 cells. We detected high TET1 levels in SET-accumulating cells and decreased TET1 levels after SET knockdown (Figure [4A](#F4){ref-type="fig"}).

![Loss of DNA methylation is associated with increased levels of TET1 and 5-hydroxymethylcytosine\
(**A**) Immunofluorescence assay using anti-TET1 antibody was performed in HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells to assess active DNA demethylation process. Cells from five fields were measured using ImageJ software. Graphics represent the percentage of TET1-positive cells. Red arrows indicate SET accumulation; green arrows indicate SET downregulation. (**B**) Flow cytometry assay was performed to measure the levels of 5-hydroxymethylcytosine in HEK293 and HEK293/SET cells. The respective unstained cells were used as negative controls; dead cells were excluded from the plot. The assay was performed in triplicate. \*(*p* \< 0.05) and \*\*(*p* \< 0.01).](oncotarget-08-26802-g004){#F4}

Since active demethylation converts 5-methylcytosine into 5-hydroxymethylcytosine \[[@R5]\], we also explored this product by flow cytometry. To assess exclusively the effect of the SET protein in the process, we selected the non-tumour cell line HEK293 overexpressing it (Figure [4B](#F4){ref-type="fig"}). Consistent with the TET1 levels, 5-hydroxymethylcytosine levels increased in HEK293/SET cells, suggesting that SET accumulation promotes active DNA demethylation by elevating the levels of TET1, which subsequently controls the oxidation of 5-methylcytosine and its conversion into 5-hydroxymethylcytosine.

SET accumulation downregulates gene expression through a histone deacetylation-dependent mechanism {#s2_3}
--------------------------------------------------------------------------------------------------

Although our finding have evidenced that SET promotes DNA demethylation through a well-characterized active mechanism, involving TET1 (Figure [4A](#F4){ref-type="fig"}) and 5-hydroxymethylcytosine (Figure [4B](#F4){ref-type="fig"}) \[[@R5]\], the present study also evidenced a downregulated gene expression driven by SET accumulation (Figure [2A](#F2){ref-type="fig"}). SET is a member of the INHAT complex that inhibits gene transcription through association with histones, thus preventing their acetylation by blocking the association histones-transcriptional coactivators \[[@R24]\]. To confirm the effects of SET accumulation on gene expression regulation, we performed a screening in HEK293 and HEK293/SET cells by employing a qPCR array system designed for a panel of 84 transcription factors (Table [1](#T1){ref-type="table"}). We found that 42% of the genes were downregulated and 19% were upregulated. For validation of the results, we performed qPCR for 8 genes, whose expressions were altered, in HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells (Figure [5](#F5){ref-type="fig"}). SET accumulation downregulated six genes (*ATF2*, *CTNNB1*, *HIF-1A*, *NFATC3*, *RELA*, and *STAT3*) and upregulated two genes *(ATF3* and *MYB*) (Figure [5](#F5){ref-type="fig"} - red bars). Overall, SET knockdown promoted the opposite effect (Figure [5](#F5){ref-type="fig"} - green bars). We also assessed the effects of SET accumulation on the regulation of expression via promoters of two transcription factors, *NFkB* and *STAT3*, by using a luciferase reporter assay. *NFkB*, which was upregulated as assessed by qPCR array analysis, presented increased levels in SET-accumulating cells (Figure [6A](#F6){ref-type="fig"} - above). In agreement with the qPCR array results, *STAT3* presented decreased levels in SET-accumulating cells (Figure [6A](#F6){ref-type="fig"}, below). These results confirm our previous findings that augmented SET levels control the expression of genes associated with tumorigenesis in HNSCC.

###### Human transcription factors qPCR array performed in HEK293 and HEK293/SET cells

  *Gene ID*   *mRNA Fold Expression*   *Expression Levels*   *Gene ID*   *mRNA Fold Expression*   *Expression Levels*
  ----------- ------------------------ --------------------- ----------- ------------------------ ---------------------
  AR          0.3528                   decreased             MEF2B       0.7254                   ns
  ARNT        1.0769                   ns                    MEF2C       0.9375                   ns
  ATF1        1.523                    ns                    MYB         5.3034                   increased
  ATF2        0.4435                   decreased             MYC         0.3888                   decreased
  ATF3        8.6154                   increased             MYF5        \-                       \-
  ATF4        1.4814                   ns                    MYOD1       1.4016                   ns
  CEBPA       1.3537                   ns                    NFAT5       0.4225                   decreased
  CEBPB       0.3071                   decreased             NFATC1      0.2906                   decreased
  CEBPG       1.5877                   ns                    NFATC2      0.4404                   decreased
  CREB1       2.9627                   increased             NFATC3      0.4331                   decreased
  CREBBP      2.5614                   increased             NFATC4      2.095                    increased
  CTNNB1      0.3136                   decreased             NFKB1       2.5437                   increased
  DR1         1.1072                   ns                    NFYB        \-                       \-
  E2F1        0.3455                   decreased             NR3C1       0.6359                   ns
  E2F6        2.1095                   increased             PAX6        0.9506                   ns
  EGR1        2.1095                   increased             POU2AF1     \-                       \-
  ELK1        1.0259                   ns                    PPARA       0.7056                   ns
  ESR1        1.4015                   ns                    PPARG       2.2925                   increased
  ETS1        1.2032                   ns                    RB1         1.8881                   ns
  ETS2        1.5125                   ns                    REL         0.4411                   decreased
  FOS         1.2457                   ns                    RELA        0.4196                   decreased
  FOXA2       0.4375                   decreased             RELB        2.4401                   decreased
  FOXO1       1.4711                   ns                    SMAD1       0.4483                   decreased
  GATA1       \-                       \-                    SMAD4       1.4112                   ns
  GATA2       0.4343                   decreased             SMAD5       5.1228                   increased
  GATA3       0.2012                   decreased             SMAD9       0.4887                   decreased
  GTF2B       3.046                    increased             SP1         2.6517                   increased
  GTF2F1      1.4917                   ns                    SP3         1.9412                   ns
  HAND1       0.4284                   decreased             STAT1       0.4872                   decreased
  HAND2       0.9246                   ns                    STAT2       0.2826                   decreased
  HDAC1       1.6323                   ns                    STAT3       0.4722                   decreased
  HIF1A       0.4108                   decreased             STAT4       1.7739                   ns
  HNF4A       1.4015                   ns                    STAT5A      0.3136                   decreased
  HOXA5       0.4311                   decreased             STAT5B      3.2873                   increased
  HSF1        2.3245                   increased             STAT6       1.3918                   ns
  ID1         1.22                     ns                    TBP         0.4508                   decreased
  IRF1        0.4294                   decreased             TCF1        \-                       \-
  JUN         0.4053                   decreased             TCF7L2      1.4015                   ns
  JUNB        0.6359                   ns                    TFAP2A      0.3384                   decreased
  JUND        0.4165                   decreased             TGIF1       2.4913                   increased
  MAX         0.4313                   decreased             TP53        0.4815                   decreased
  MEF2A       0.6493                   ns                    YY1         1.3076                   ns

mRNA fold change expression was calculated using PCR array Data Analysis Software (Qiagen). Genes with fold expression value below 0.5 were considered downregulated, and genes with fold expression value above 2.0 were considered up-regulated. ns (non-significant).

![Gene expression of human transcription factors is downregulated through SET protein\
Quantitative real time PCR was performed to validate the gene expression of six transcription factors downregulated by SET (*ATF2*, *CTNNB1*, *HIF-1A*, *NFATC3*, *RELA*, and *STAT1*) and two transcription factors upregulated by SET (*ATF3* and *MYB*), using SybrGreen primers in HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells. Graphics represent relative quantification of experiments performed in triplicate through the 2^−ΔΔCt^ method. CDNA from HEK293 cells was used as calibrator; GAPDH and β-globin primers were used as housekeeping.](oncotarget-08-26802-g005){#F5}

![SET contributes to low gene expression levels through chromatin association\
(**A**) Luciferase reporter assay was performed to quantify NFkB and STAT3 expression induced by SET accumulation. HEK293 cells were transfected with plasmids containing cDNA to overexpress SET, and plasmids with gene promoter region for *NFkB* (PGL3-NFkB-Luc) and *STAT3* (PGL3-STAT3-Luc). (**B**) Western blot assay was used to assess whether downregulation of gene expression could be controlling protein levels. Total proteins were obtained from HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells. ATF1, CREB, NFkB, NFATC3, STAT1, STAT3, SET, and β-actin proteins were analyzed. Red arrows indicate SET accumulation; green arrows indicate SET downregulation. (**C**) Chromatin immunoprecipitation assay was performed to assess whether SET is able to downregulate the expression of transcription factor genes through binding to the promoter. DNA of the respective cells was immunoprecipitated with anti-SET antibody, and PCR was performed using primers for HIF-1A, NFATC3, and NFkB promoters. Ctrl lanes represent samples immunoprecipitated using anti-IgG antibody; INPUT samples consist of total DNA; SET lanes refer to DNA immunoprecipitated with anti-SET antibody.](oncotarget-08-26802-g006){#F6}

Next, we assessed whether protein levels of the transcription factors regulated by SET correlate with their respective mRNA levels. Western blotting analysis of six transcription factors (ATF1, CREB, NFkB, NFATC3, STAT1, and STAT3) demonstrated the existence of such correlation. In line with the gene expression data, the ATF1, CREB, and NFkB protein levels were elevated, and the NFATC3, STAT1, and STAT3 protein levels were diminished in SET-accumulating cells (Figure [6B](#F6){ref-type="fig"}).

Genes in an inactive state exhibit promoters that are hypoacetylated and allow SET binding to chromatin, thereby blocking the access of histone acetyltransferases and preventing gene expression \[[@R24]\]. Given that 42% of the transcription factors were downregulated in HEK293/SET cells, we assessed whether SET protein interacts with chromatin to downregulate their expression. We performed the ChIP assay for the promoter region of *HIF-1A* and *NFATC3*, which were downregulated by SET (Figure [5](#F5){ref-type="fig"}), and of *NFkB*, which was upregulated by SET (Figure [6A](#F6){ref-type="fig"}). In SET-accumulating cells (HEK293/SET, HN12, and HN13), SET interacted with *HIF-1A* and *NFATC3* chromatin, but not with *NFkB* chromatin (Figure [6C](#F6){ref-type="fig"}).

SET binds to hypoacetylated histones and interacts with histone deacetylases, inhibiting the access of histone acetyltransferases to chromatin \[[@R13]\]. In this context, we assessed by Western blot whether SET accumulation changes the H2B and H3 acetylation levels (Figure [7A](#F7){ref-type="fig"}). Consistent with our previous report that SET decreases histone H4 acetylation \[[@R23]\], SET accumulation lowered both H2B and H3 acetylation levels, while SET knockdown elevated H2B and H3 acetylation; it suggests a mechanism of gene expression regulation mediated by SET that involves histone acetylation. As SET associates with class I and II histone deacetylases (HDACs) at deacetylated promoters to prevent histone acetylation and arrest gene expression \[[@R24]\], next, we used an immunofluorescence assay to assess the effects of SET accumulation on histone deacetylase 1 (HDAC1). As expected, SET accumulation and SET knockdown were associated with augmented and diminished HDAC1 levels, respectively (Figure [7B](#F7){ref-type="fig"}).

![SET may modulate gene expression through hypoacetylation of histones and increase of HDAC1 levels\
(**A**) Western blot assay was performed by adding antibodies against acetyl-H2B, acetyl-H3, SET, and β-actin to total proteins extracted from HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells. (**B**) HDAC1 levels were assessed using immunofluorescence assay. Cells from five fields were measured using ImageJ software. Graphics represent the percentage of TET1-positive cells. Red arrows indicate SET accumulation; green arrows indicate SET downregulation. (**C**) To assess whether SET directly associates with sites of hypoacetylated gene promoter, HEK293 and HEK293/SET cells were treated with the histone deacetylase inhibitor Trichostatin A (TSA; 100 ng/mL) for 24 h. After cell lysis, chromatin was immunoprecipitated with anti-SET antibody and PCR was performed using primers that recognize the promoter of *HIF-1A* and *NFATC3*. INPUT samples consist of total DNA; SET lanes refer to DNA immunoprecipitated with anti-SET antibody. (**D**) Western blot assay using antibodies against acetyl-H2B, acetyl-H3, SET, and β-actin was performed with total proteins from the respective cells treated with TSA (100 ng/mL) for 24 h.](oncotarget-08-26802-g007){#F7}

To demonstrate the role that SET protein plays in the promoter silencing through its direct interaction with hypoacetylated histones, we selected the pharmacological HDAC inhibitor, TSA (Trichostatin A), to increase histone acetylation levels \[[@R27]\]. After SET overexpression, HEK293 cells were treated with TSA, and a ChIP assay was performed to evaluate the capability of SET-promoter interaction (Figure [7C](#F7){ref-type="fig"}). We analysed the promoter of *HIF-1A* and *NFATC3*, which were downregulated by the SET-promoter interaction (Figure [6C](#F6){ref-type="fig"}). For both genes, TSA decreased the SET-promoter interaction (Figure [7C](#F7){ref-type="fig"} - black arrow). Western blot analysis of the efficacy of the TSA treatment demonstrated that it elevated the levels of acetylated histones H2B and H3, and remarkably diminished the SET protein levels (Figure [7D](#F7){ref-type="fig"}).

Epigenetic control of gene expression mediated by SET accumulation is more effective through mechanisms involving histone acetylation {#s2_4}
-------------------------------------------------------------------------------------------------------------------------------------

As demonstrated above, SET accumulation promotes DNA hypomethylation through a mechanism of active DNA demethylation involving increased TET1 and 5-hydroxymethylcytosine generation. Controversially, SET decreased histone acetylation levels and expression of transcription factor genes. DNA methylation and histone acetylation are the most studied epigenetic modifications in the context of gene expression. Methylation of gene promoters may trigger deacetylation of histones and hypoacetylated histones may sensitize to targeted DNA methylation \[[@R28]\]. In this sense, we assessed the relationship between SET protein and gene expression using two pharmacological agents, 5-aza-2′-deoxycytidine (5-AZA) and TSA, to inhibit DNA methylation and activate histone acetylation, respectively. We performed qPCR in HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells to determine how the loss of methylation and gain of acetylation affect the expression of genes previously identified as being regulated by SET protein. By using a relative quantification method \[[@R29]\], we assessed the potential of pharmacological agents to restore the gene expression levels close to those observed in cells without SET accumulation. In general, TSA was more effective than 5-AZA to reverse the effect of SET protein accumulation on gene expression (Figure [8A](#F8){ref-type="fig"}). Therefore, SET accumulation likely represses gene expression through a histone hypoacetylation-associated mechanism.

![Histone acetylation is more effective than DNA demethylation in reactivating gene expression in SET-accumulating cells\
(**A**) Quantitative real time PCR was performed using cDNA from HEK293, HEK293/SET, HN12, HN12siSET, HN13, and HN13siSET cells treated with 100 ng/mL TSA (histone deacetylase inhibitor) or 10 μM 5-aza-2\'-deoxicytidine (DNA methyltransferase inhibitor). *BRCA1*, *MLH1*, and *PTEN* were assessed through TaqMan probes, and *GSTP1*, *HIF-1A*, *NFATC3*, and *STAT1* through SybrGreen primers. Graphics represent relative quantification of experiments performed in triplicate, calculated using the 2^−ΔΔCt^ method. CDNA from HEK293 cells was used as calibrator; GAPDH and β-globin primers were used as housekeeping. \*(*p* \< 0.05), \*\*(*p* \< 0.01), \*\*\*(*p* \< 0.001) and ns (non-significant). (**B**) Transmission electron microscopy was performed in HEK293 and HEK293/SET cells to analyze chromatin compaction.](oncotarget-08-26802-g008){#F8}

Regulation of gene expression depends on histone modifications, such as histone acetylation/methylation, DNA methylation, chromatin remodeling enzymes and effector proteins that, in association, influence the structure and function of chromatin \[[@R30]\]. In addition, evidence suggests an interplay between DNA methylation and histone deacetylation in the silencing of gene transcription \[[@R28]\]. Given that our results indicated that SET accumulation promotes DNA demethylation and histone deacetylation, as well as downregulation of genes, we assessed whether these epigenetic modifications, promoted by SET accumulation, could reflect modifications in chromatin organization. Transmission electron microscopy (TEM) images revealed that SET-accumulating HEK293 cells presented an increase in electron-dense material scattered by the nucleus, which was compatible with chromatin structure, despite exhibiting a loss of the heterochromatin associated with the nuclear lamina (Figure [8B](#F8){ref-type="fig"}). These results may explain how SET regulates gene expression levels though histone deacetylation and chromatin condensation: together, they could be promoting the repression of transcription.

DISCUSSION {#s3}
==========

SET protein, which was first described as stimulating DNA replication and transcription of the adenovirus genome protein \[[@R31]\], has been associated with multiple actions involved in chromatin remodeling and transcription control \[[@R10], [@R13], [@R32]--[@R34]\]. A SET function linking epigenetic modifications and gene expression has not yet been described. In this context, and considering that SET accumulates in HNSCC \[[@R9], [@R15]\], we assessed whether SET accumulation could interfere with epigenetic and gene expression control to contribute to cancer development. Here, we demonstrated that SET accumulation is associated with loss of DNA methylation, apparently through active DNA demethylation signaling and, remarkably, reduced methylation levels seem not to directly correlate with gene expression control.

HNSCC is a heterogeneous disease in which DNA methylation status changes according to clinical, environmental, and genetic factors \[[@R35]\]. DNA global hypomethylation has been reported in HNSCC and has been associated with tumour progression, regardless of the methylation status of the gene promoter regions \[[@R36]\]. As expected, we found that three HNSCC cell lines exhibited diminished DNA methylation when compared with normal oral keratinocyte spontaneously immortalized (NOK-SI) and HEK293 cells. SET protein knockdown through RNA interference recovered the DNA methylation status, which was accompanied by augmented 5-methylcytidine levels, indicating that SET participates in the control of global methylation by promoting loss of methylation in HNSCC. However, loss of methylation was not followed by increased expression of the genes analysed. According to TEM images, loss of methylation resulting from SET accumulation may be associated with either reactivation of elements of peripheral heterochromatin, repetitive elements or oncogene activation. These are factors known to favour carcinogenesis \[[@R37], [@R38]\].

Loss of DNMT1 leads to progressive DNA demethylation through a passive mechanism \[[@R26], [@R39]\]. It is worth to note that SET accumulation increased both DNMT1 protein levels and enzymatic activity. This finding suggests that the DNA demethylation mechanism associated with SET accumulation is not mediated by DNMT1 loss in a passive manner \[[@R40]\]. DNMT1 is the major enzyme that maintains the cellular DNA methylation levels \[[@R41]\] but, in tumour cells, DNMT1 up-regulation is associated with cellular transformation in tumours presenting both global hyper- or hypomethylation \[[@R42]--[@R44]\].

One explanation for the loss of methylation promoted by SET involves the active DNA demethylation process, based on TET proteins that successively oxidize 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine, which in turn can be removed from DNA through a base excision repair mechanism \[[@R40], [@R45]\]. Accordingly, we demonstrated that SET accumulation is associated with a rise in TET1 and 5-hydroxymethylcytosine levels, suggesting the involvement of SET in the active DNA demethylation through accumulation of TET1, which in turn drives 5-hydroxymethylcytosine formation.

Our initial hypothesis that global loss of methylation would result in increased expression of all studied genes was not confirmed; in fact, SET protein downregulated most of the genes analyzed. Recent studies have demonstrated that specific histone modifications can mediate gene repression in cancer cells in the gene promoter region through a DNA methylation state-independent mechanism \[[@R46]--[@R48]\]. In addition, it has been proposed that, rather than a mechanism to stably lock gene expression, DNA methylation works as a marker to maintain gene silencing \[[@R49], [@R50]\]. Surprisingly, SET accumulation did not increase the expression of the hypomethylated genes analyzed, suggesting that SET regulates gene expression through a mechanism independent of DNA methylation of the gene promoter regions. Given that SET accumulation inhibits histone acetylation \[[@R13]\], we assessed whether SET negatively regulates gene expression by controlling the histone acetylation process.

Lysine acetylation in histone tails relaxes the chromatin structure and favours gene transcription \[[@R51], [@R52]\]. SET protein was identified in association with hypoacetylated histones, maintaining the gene silencing \[[@R23], [@R24]\]. Here, we found that SET accumulation lowered the expression of most of the genes analysed, regardless of DNA methylation state. Given that histone deacetylase inhibitors can reactivate gene expression without loss of methylation \[[@R50]\], we used TSA, a pharmacological HDAC inhibitor, to increase histone acetylation and 5-AZA, a demethylating agent, to inhibit DNA methylation. By exploring the gene expression levels, our results demonstrated that TSA was more effective than 5-AZA in recovering the gene expression close to basal levels, suggesting that *(i)* the main mechanism of gene transcription silencing involves histone hypoacetylation and chromatin compacting in SET-accumulating cells, and *(ii)* this mechanism is independent of the DNA methylation status.

This study provides evidence supporting that SET accumulation is important for tumorigenesis in HNSCC. SET would regulate the expression of several genes associated with cell differentiation, DNA damage repair, and development that we investigated, such as transcription factors and tumour suppressors (*STAT1, STAT3, NFkB, NFATC3, MLH1, PTEN, BRCA1, HIF1A, ATF1*, and *CREB*). Furthermore, DNA demethylation, associated with SET accumulation, may also favour HNSCC tumorigenesis by, for example, reactivating heterochromatin elements as repetitive sequences and oncogenes.

Overall, SET accumulation is implicated in epigenetic modifications, such as DNA hypomethylation and histone hypoacetylation. It is associated with gene expression regulation and chromatin organization, thereby affecting gene expression control, DNA damage repair, and genome instability. Certainly, SET protein activity can contribute to HNSCC development. We propose HDAC inhibitors as potential pharmacological agents to recovery gene expression in SET-accumulating tumours.

MATERIALS AND METHODS {#s4}
=====================

Cell lines and transfection {#s4_1}
---------------------------

Head and neck squamous cell carcinomas (HNSCCs) HN6, HN12, and HN13 \[[@R53]\], HEK293 (human embryonic kidney; ATCC, Manassas, VA, USA) and NOK-SI (normal oral keratinocytes) \[[@R54]\] cell lines were cultured in DMEM supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 mg/ml) (Sigma-Aldrich, St. Louis, MO, USA), at 37°C, in a humidified atmosphere containing 5% CO~2~.

For assays using SET overexpression, HEK293 and NOK-SI cells were transfected with SET DNA construction using the PolyFect Reagent (Qiagen, Valencia, CA, USA) following the manufacturer\'s instructions: HEK293/SET and NOK-I/SET, respectively. A *SET* human full-length cDNA clone (pCMV SPORT6; NM_003011.3) was purchased from Invitrogen and transferred to a pcDNA3.1 vector (Invitrogen - Thermo-Fisher Scientific - Waltham, MA, USA). Negative control cells were transfected using a pcDNA3.1 empty vector.

For assays using SET knockdown, HNSCC cell lines were transfected with double-stranded RNA oligonucleotides directed against *SET* (GS6418; Qiagen, Valencia, CA, USA) using HiPerFect Transfection Reagent (Qiagen, Valencia, CA, USA) following the manufacturer\'s instructions: HN6siSET, HN12siSET, and HN13siSET, respectively. The si*CONTROL* AllStars siRNA Negative Control (Qiagen, Valencia, CA, USA) was used as a negative siRNA control.

DNA methylation analysis {#s4_2}
------------------------

Genomic DNA was isolated from cell lines through digestion with proteinase K followed by phenol-chloroform extraction and ethanol precipitation. Genomic DNA (1 μg) from HNSCC (control or with SET knockdown), HEK293 and NOK-SI (control or with SET overexpression) cells were digested using the EpitTect methyl DNA restriction Kit (Qiagen, Valencia, CA, USA) according to the manufacturer\'s instructions, and tumour suppressor gene EpiTect methyl qPCR Arrays (Qiagen, Valencia, CA, USA) were applied.

Analysis of 5-methylcytidine and 5-hydroxymethylcytosine levels by using flow cytometry {#s4_3}
---------------------------------------------------------------------------------------

The protocol was performed as previously described \[[@R55]\]. Briefly, cells were washed twice with phosphate buffered saline (PBS) pH 7.4 supplemented with 1% bovine serum albumin (BSA) and 0.1% Tween 20 (PBST-BSA), and fixed with 0.25% paraformaldehyde. Cells were maintained at 4°C for 10 min before addition of 9 vol of methanol/PBS. Then, cells were treated with 2 N HCl at 37°C and with 0.1 M borate buffer pH 8.5. Samples were treated with RNase (10 mg/mL), blocked with PBST-BSA and incubated with anti-5-methylcytidine (sc-56615 - Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 5-hydroxymethylcytosine (ab214728 - Abcam, Cambridge, MA, USA). After incubation with TRITC-conjugated secondary antibody for 1 h, cells were analysed using Guava easyCyte^™^ (Millipore, Billerica, MA, USA) cytometer.

RNA extraction and real time PCR {#s4_4}
--------------------------------

RNA was isolated from cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer\'s protocol. RQ1 RNase-Free DNase (Promega, Madison, WI, USA) was used to treat RNA. cDNA synthesis was performed using a SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) protocol.

The mRNA sequences were obtained from NCBI database ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)), and primers ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) were constructed using the Gene Runner program (version 3.05, Hastings Software, Inc.). Reactions were performed in a medium (10 μL) containing 5 μL Fast EvaGreen Master Mix (Uniscience, Cambridge, U.K.), 0.3 μM per primer, and 100 ng cDNA in a Mastercycler ep-Realplex thermocycler (Eppendorf, Hamburg, Germany). *BRCA1* (Hs01556193_m1), *MLH1* (Hs00979919_m1) and *PTEN* (Hs02621230_s1) mRNA levels were assessed by TaqMan assay (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer\'s protocol.

Immunofluorescence assay {#s4_5}
------------------------

Cells were placed on glass coverslips in 24-well plates and fixed with methanol for 6 min, at −20°C. In addition, 0.5% (v/v) Triton X-100 in PBS and 3% (w/v) BSA was used for blocking. Primary antibodies anti-DNMT1 (\#D59A4) and HDAC1 (\#10E2) (Cell signaling, Danvers, MA, USA) and anti-TET1 (\#sc-163443 - Santa Cruz Biotechnology, Santa Cruz, CA, USA) were incubated overnight. After incubation with an Alexa Fluor 546-, FITC- or TRITC-conjugated secondary antibody for 1 h, the cells were stained with DAPI (Sigma-Aldrich, St Louis, MO, USA) and visualized using a Zeiss Axiovert 40 CFL Microscope and Zeiss AxioVision 4.8.2 software (Munich, German).

DMNT activity assay {#s4_6}
-------------------

Protein fractions were obtained using ProteoJET™ Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas - Thermo-Fisher Scientific - Waltham, MA, USA), according to the manufacturer\'s instructions. Nuclear fractions were subjected to a DNA methyltransferase activity assay using EpiSeeker DNMT Activity Quantification Kit (Abcam, Cambridge, MA, USA) according to the manufacturer\'s protocol.

Human transcription factor PCR array {#s4_7}
------------------------------------

Total RNA was isolated from cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Complementary DNA was synthetized using an RT^2^ first strand kit (SABioscience - Qiagen, Valencia, CA, USA). Real time PCR was performed using an RT^2^ Profiler PCR array system (SABioscience - Qiagen, Valencia, CA, USA) with SYBR Green PCR Master Mix, according to manufacturer\'s instructions, in a Mastercycler ep-Realplex thermocycler (Eppendorf, Hamburg, Germany).

Luciferase reporter assay {#s4_8}
-------------------------

The protocol was performed as previously described \[[@R56]\]. Briefly, HEK293 cells were transfected with SET pcDNA3.1 and pGL3-NFκB-*Luc* or pGL3-STAT3-*Luc* (kindly provided by Dr. Squarize) \[[@R56]\] promoter reporter constructs containing firefly luciferase cDNA, and pRL-null normalization construct containing *Renilla* luciferase from *Renilla reniformis*. Firefly and *Renilla* luciferase activity were measured in the cellular extract using Dual-Glo^®^ Luciferase Assay System (Promega, Madison, WI, USA), 24 h after transfection in a luminometer (AutoLumat LB 953, Berthold).

Chromatin immunoprecipitation assay (ChIP) {#s4_9}
------------------------------------------

ChIP assay was performed as previously described \[[@R23]\]. Cells were cross-linked with 1% formaldehyde and then lysed. The DNA-protein complexes were immunoprecipitated with anti-SET (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and protein G agarose beads (GE HealthCare, Piscataway, NJ, USA). DNA was extracted with phenol/chloroform post-reversing of the DNA-protein crosslinks. PCR reaction was performed using the sequence primers for *GSTP1*, *HIF-1A*, *NFATC3*, *NFkB* and *PTEN* ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). PCR products were analysed using 1.5% agarose gel.

Immunoblotting assay {#s4_10}
--------------------

Cultured cells were harvested and sonicated, and protein concentration of the cellular extract was determined through DC protein assay (Bio-Rad, Hercules, CA, USA). Aliquots of total protein (30--50 μg) from each sample were resolved by sodium dodecyl sulphate (SDS) PAGE and transferred to a PVDF membrane. The membrane was incubated overnight with primary antibodies for ATF1 (\#ab208436 - Abcam, Cambridge, MA, USA), CREB (\#9197), acetyl-H2B (Lys20) (\#2571) acetyl-H3 (Lys9) (\#9649), Histone H3 (\#9715), p65/NFkB (\#3034), NFATC3 (\#4998), STAT1 (\#9172), STAT3 (\#12640) (Cell signaling, Danvers, MA, USA), SET (sc-133138) and β-actin (sc-47778) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membrane was washed and incubated with secondary antibodies conjugated with horseradish peroxidase for 1 h. Bound antibodies were detected using an ECL Western blotting system (GE Healthcare, Little Chalfont, UK).

Transmission electron microscopy {#s4_11}
--------------------------------

HEK293 and HEK293/SET cells were collected after trypsin digestion, washed in fresh PBS (pH 7.4), fixed by immersion in glutaraldehyde, post-fixed in osmium tetroxide, stained in block with uranium acetate, dehydrated, and embedded in resin (Embed 812, EM Sciences). Ultrathin sections (60 nm) were collected on Pioloform (Ted Pella, Redding, CA) and carbon-coated single sloth grids and contrasted with uranyl acetate and lead citrate. Cells were examined on a ZEISS LEO 906 electron microscope.

Statistical analyses {#s4_12}
--------------------

Statistical analyses were performed using GraphPad Prism software (version 5.0, USA). Student\'s *t-test* or ANOVA was used to examine the association between media and treatments. *P* values \< 0.05 were considered significant.
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